X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1622) 1622
Publication (248) 248
Book Review (16) 16
Conference Proceeding (5) 5
Book Chapter (3) 3
Magazine Article (3) 3
Newsletter (2) 2
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1103) 1103
index medicus (886) 886
animals (751) 751
aminopyridines - therapeutic use (744) 744
aminopyridines - pharmacology (705) 705
male (638) 638
female (547) 547
pharmacology & pharmacy (385) 385
mice (305) 305
middle aged (280) 280
rats (278) 278
adult (254) 254
aminopyridines - administration & dosage (249) 249
aminopyridines - adverse effects (221) 221
benzamides - therapeutic use (219) 219
dose-response relationship, drug (203) 203
aged (196) 196
cyclopropanes - therapeutic use (174) 174
oncology (171) 171
neurosciences (158) 158
pulmonary disease, chronic obstructive - drug therapy (156) 156
treatment outcome (153) 153
article (148) 148
roflumilast (147) 147
4-aminopyridine (146) 146
cell line, tumor (143) 143
benzamides - pharmacology (141) 141
cancer (133) 133
disease models, animal (132) 132
research (130) 130
respiratory system (126) 126
aminopyridines - chemistry (124) 124
aminopyridines - pharmacokinetics (124) 124
amrinone (119) 119
analysis (118) 118
mutation (118) 118
care and treatment (117) 117
cyclopropanes - pharmacology (112) 112
drug therapy (109) 109
rats, sprague-dawley (109) 109
phosphodiesterase 4 inhibitors - therapeutic use (108) 108
obstructive pulmonary-disease (105) 105
aminopyridines (100) 100
double-blind method (99) 99
in-vitro (99) 99
administration, oral (97) 97
time factors (95) 95
heart failure - drug therapy (93) 93
inflammation (92) 92
expression (91) 91
antineoplastic agents - pharmacology (87) 87
kinases (87) 87
biochemistry & molecular biology (86) 86
cell proliferation - drug effects (86) 86
mice, inbred c57bl (85) 85
cardiotonic agents - therapeutic use (82) 82
drug therapy, combination (81) 81
indoles - pharmacology (81) 81
benzamides - adverse effects (80) 80
apoptosis (79) 79
phosphorylation (79) 79
breast neoplasms - drug therapy (78) 78
proteins (78) 78
activation (77) 77
chronic obstructive pulmonary disease (77) 77
signal transduction - drug effects (77) 77
adolescent (74) 74
chemistry, medicinal (74) 74
in vitro techniques (74) 74
cell biology (73) 73
clinical trials as topic (73) 73
cyclopropanes - adverse effects (73) 73
cystic fibrosis - drug therapy (73) 73
clinical neurology (72) 72
copd (72) 72
quinolones - therapeutic use (71) 71
dosage and administration (69) 69
antineoplastic agents - therapeutic use (68) 68
morpholines - pharmacology (68) 68
young adult (68) 68
asthma (67) 67
benzamides - administration & dosage (67) 67
pharmacology (67) 67
protein kinase inhibitors - pharmacology (67) 67
rodents (67) 67
xenograft model antitumor assays (67) 67
benzodioxoles - therapeutic use (66) 66
clinical trials (66) 66
research article (66) 66
apoptosis - drug effects (65) 65
multidisciplinary sciences (65) 65
phosphodiesterase inhibitors - therapeutic use (65) 65
psychiatry (65) 65
breast cancer (64) 64
cystic fibrosis transmembrane conductance regulator - genetics (63) 63
efficacy (63) 63
piperazines - pharmacology (63) 63
inhibitors (62) 62
medicine & public health (62) 62
phosphodiesterase 4 inhibitors - pharmacology (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1520) 1520
German (45) 45
Russian (14) 14
Spanish (12) 12
French (9) 9
Japanese (9) 9
Chinese (8) 8
Italian (6) 6
Polish (2) 2
Romanian (2) 2
Turkish (2) 2
Ukrainian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9971, pp. 857 - 866
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9691, pp. 695 - 703
Summary Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the... 
Internal Medicine | PDE4 INHIBITOR ROFLUMILAST | MEDICINE, GENERAL & INTERNAL | IN-VITRO | PHOSPHODIESTERASE-4 INHIBITORS | MANAGEMENT | THERAPY | INFLAMMATION | THEOPHYLLINE | FLUTICASONE | COPD | SALMETEROL | Bronchodilator Agents - therapeutic use | Phosphodiesterase Inhibitors - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - etiology | Cyclopropanes - therapeutic use | Vital Capacity - drug effects | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Phosphodiesterase 4 Inhibitors | Female | Drug Therapy, Combination | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Salmeterol Xinafoate | Double-Blind Method | Administration, Oral | Administration, Inhalation | Albuterol - analogs & derivatives | Treatment Outcome | Regression Analysis | Analysis of Variance | Smoking - epidemiology | Albuterol - therapeutic use | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Dosage and administration | Enzyme inhibitors | Research | Drug therapy | Bronchodilator agents | Studies | Smoking cessation | Molecular structure | Clinical trials | Chronic obstructive pulmonary disease | Clinical medicine | Headache | Respiratory function | Side effects | Motivation | salmeterol | Lung | Bronchodilators | Diarrhea | Nausea
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9691, pp. 685 - 694
Summary Background The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exacerbations in certain patients with chronic... 
Internal Medicine | PDE4 INHIBITOR ROFLUMILAST | MEDICINE, GENERAL & INTERNAL | FLUTICASONE PROPIONATE | SPUTUM | INFLAMMATION | COPD EXACERBATIONS | PREVENTION | TIOTROPIUM | STATISTICAL-ANALYSIS | HEALTH-STATUS | SALMETEROL | Phosphodiesterase Inhibitors - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - etiology | Cyclopropanes - therapeutic use | Vital Capacity - drug effects | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Phosphodiesterase 4 Inhibitors | Female | Benzamides - pharmacology | Adrenergic beta-Agonists - therapeutic use | Drug Therapy, Combination | Cholinergic Antagonists - therapeutic use | Cyclopropanes - pharmacology | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Administration, Oral | Proportional Hazards Models | Phosphodiesterase Inhibitors - pharmacology | Treatment Outcome | Regression Analysis | Analysis of Variance | Smoking - epidemiology | Aminopyridines - pharmacology | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Dosage and administration | Enzyme inhibitors | Research | Drug therapy | Studies | Clinical trials | Chronic obstructive pulmonary disease | Health economics | Disease management | Corticoids | Respiratory function | Side effects | Historical account | Motivation | Smoking | air flow
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Journal Article
Blood, ISSN 0006-4971, 12/2017, Volume 130, Issue 23, pp. 2469 - 2474
In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and... 
ADULT PATIENTS | TREATMENT-NAIVE | OLDER PATIENTS | INDUCTION CHEMOTHERAPY | LOW-DOSE CYTARABINE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | TRANS-RETINOIC ACID | KINASE INHIBITOR | GREATER-THAN-OR-EQUAL-TO-65 YEARS | HEMATOLOGY | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Triazines - therapeutic use | Humans | Leukemia, Myeloid, Acute - metabolism | Staurosporine - analogs & derivatives | Isocitrate Dehydrogenase - antagonists & inhibitors | Molecular Targeted Therapy | fms-Like Tyrosine Kinase 3 - genetics | Aminopyridines - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Daunorubicin - administration & dosage | Triazines - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Clinical Trials as Topic | Sulfonamides - pharmacology | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Sulfonamides - therapeutic use | Staurosporine - therapeutic use | Aminopyridines - pharmacology | Sialic Acid Binding Ig-like Lectin 3 - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Liposomes | Mutation | Aminoglycosides - pharmacology | Staurosporine - pharmacology | Aminoglycosides - therapeutic use | Leukemia, Myeloid, Acute - genetics
Journal Article
BMC Pulmonary Medicine, ISSN 1471-2466, 11/2015, Volume 15, Issue 1, p. 145
Journal Article